Metabolic changes following subthalamotomy for advanced Parkinson's disease.
We studied 6 advanced-stage Parkinson's disease patients with [18F] fluorodeoxyglucose/positron emission tomography before and 3 months after unilateral ablation of the subthalamic nucleus performed with microelectrode mapping. Operative changes in glucose metabolism were assessed by comparing baseline and postoperative scans. We also quantified operative changes in the activity of an abnormal Parkinson's disease-related metabolic network that we had identified in previous [18F] fluorodeoxyglucose/positron emission tomography studies. Following unilateral subthalamic nucleus ablation, a highly significant reduction in glucose utilization was present in the midbrain ipsilateral to the lesion site, most pronounced in the vicinity of the substantia nigra pars reticularis. Significant metabolic reductions were also present in the ipsilateral internal globus pallidus, ventral thalamus, and pons. Operative changes in Parkinson's disease network activity differed significantly for the lesioned and unlesioned hemispheres. In the lesioned hemisphere, network activity declined significantly following surgery, but was unaltered in the contralateral, unlesioned hemisphere. These results suggest that subthalamotomy reduces basal ganglia output through internal globus pallidus/substantia nigra pars reticularis and also influences downstream neural activity in the pons and ventral thalamus. This procedure also reduces the activity of abnormal Parkinson's disease-related metabolic brain networks, suggesting a widespread modulation of motor circuitry.
Su
P C
PC
Department of Neurology, National Taiwan University Hospital, Taipei.
Ma
Y
Y
Fukuda
M
M
Mentis
M J
MJ
Tseng
H M
HM
Yen
R F
RF
Liu
H M
HM
Moeller
J R
JR
Eidelberg
D
D
D000328:Adult; D002529:Cerebellar Nuclei / Q000378:metabolism; D005260:Female; D019788:Fluorodeoxyglucose F18; D005917:Globus Pallidus / Q000378:metabolism; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000601:surgery*; D011149:Pons / Q000378:metabolism; D019275:Radiopharmaceuticals; D020531:Subthalamic Nucleus / Q000601:surgery*; D013788:Thalamus / Q000378:metabolism; D014055:Tomography, Emission-Computed; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D005947:Glucose